Antitumor hybrid BT009K modulates inflammation induced neovascuaralization in both tumorigenic and non-tumorigenic model system

Shamanth Neralagundi, H. G. and Zabiulla and Khanum, Shaukath Ara and Manjunatha, H. and Prabhakar, B. T. (2018) Antitumor hybrid BT009K modulates inflammation induced neovascuaralization in both tumorigenic and non-tumorigenic model system. Journal of Applied Pharmaceutical Science, 8 (4). pp. 143-149. ISSN 2231-3354

[img] Text (Full Text)
Antitumor hybrid BT009K modulates.pdf - Published Version

Download (8MB)
Official URL: http://dx.doi.org/10.7324/JAPS.2018.8421

Abstract

Cancer being one of the most dreadful diseases and inflammation in cancer is one of the emerged Hallmarks of cancer. Discovering new drugs with minimal side effects plays a vital role in drug development process for the treatment of cancer. As an approach antitumor hybrid of “Benzophenone coupled with diamide analog “BT009K” or N-(2-{2-[4-(4-bromo-benzoyl)-2-methyl-phenoxy]-acetylamino}-phenyl)-2-[2-methyl-4-(2-methyl-benzoyl)-phenoxy] was screened against different cell lines. Cytotoxic effect was found to be effective against EAC with prolonged effect. The in-vivo antitumor effect was observed in EAC ascites tumor model system with reduced peritoneal neovascularisation. Further histological examination with endothelial marker CD31 confirmed the angioregressive effect of BT009K. The results were additionally confirmed in a non-tumorigenic model like CAM and rat corneal angiogenesis assay indicating reduced microvessel density count by BT009K. Further BT009K induces the anti-invasive effect in EAC cells in-vitro which could be further developed into therapeutic potential.

Item Type: Article
Subjects: C Chemical Science > Chemistry
Divisions: Yuvaraj college > Chemistry
Depositing User: manjula User
Date Deposited: 02 Nov 2019 06:00
Last Modified: 02 Nov 2019 06:00
URI: http://eprints.uni-mysore.ac.in/id/eprint/9747

Actions (login required)

View Item View Item